Alvotech and Fuji Pharma (Tokyo Stock Exchange: 4554) today announce that the two companies are entering into an exclusive partnership for the commercialization by Fuji Pharma of Alvotech’s biosimilar portfolio in Japan. Alvotech gains access to the third largest pharmaceutical market in the world

Alvotech today announced it is entering into a joint venture with Changchun High & New Technology Industries Group Inc (“CCHN”) which will enable Alvotech to develop, manufacture and commercialize its biosimilar portfolio in China. A new state-of-the-art biologics facility built in China Alvotech

Alvotech is delighted to announce that it has received manufacturing licensure from the Icelandic Medicines Agency, for its biopharmaceutical facility in Reykjavik, Iceland. The 13,000m² facility, located in the science park of the University of Iceland in Reykjavik, is dedicated to the development

Alvotech, today announces the opening of a new state-of-the-art facility, dedicated to the development and manufacturing of biosimilar monoclonal antibodies (“mAbs”). The opening of this industry leading biologics manufacturing plant marks a significant milestone for Alvotech, an independent sister

Alvotech today announced that it has closed on the acquisition of ​Baliopharm GmbH, a German biopharmaceutical development company, previously a subsidiary of Baliopharm AG. The acquisition provides Alvotech with complimentary capabilities in the area of biosimilar development.